SONN•benzinga•
Sonnet BioTherapeutics Holdings Announces Safety Results Of Son-1010 At Highest Dose Combined With Atezolizumab In Phase 1b/2a Clinical Trial In Adult Patients With Advanced Solid Tumors Or Platinum-resistant Ovarian Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 4, 2025 by benzinga